CN103945858A - 用于治疗糖尿病和相关病症的方法和组合物 - Google Patents

用于治疗糖尿病和相关病症的方法和组合物 Download PDF

Info

Publication number
CN103945858A
CN103945858A CN201280056939.9A CN201280056939A CN103945858A CN 103945858 A CN103945858 A CN 103945858A CN 201280056939 A CN201280056939 A CN 201280056939A CN 103945858 A CN103945858 A CN 103945858A
Authority
CN
China
Prior art keywords
glutamine
diabetes
compositions
body weight
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280056939.9A
Other languages
English (en)
Chinese (zh)
Inventor
新原丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmaus Medical Inc
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103945858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Priority to CN201810135122.XA priority Critical patent/CN108478551A/zh
Priority to CN201810134012.1A priority patent/CN108354916A/zh
Publication of CN103945858A publication Critical patent/CN103945858A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201280056939.9A 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物 Pending CN103945858A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810135122.XA CN108478551A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201810134012.1A CN108354916A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
US61/629,633 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201810135122.XA Division CN108478551A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201810134012.1A Division CN108354916A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Publications (1)

Publication Number Publication Date
CN103945858A true CN103945858A (zh) 2014-07-23

Family

ID=48470183

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280056939.9A Pending CN103945858A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201810134012.1A Pending CN108354916A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201810135122.XA Pending CN108478551A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810134012.1A Pending CN108354916A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物
CN201810135122.XA Pending CN108478551A (zh) 2011-11-21 2012-11-17 用于治疗糖尿病和相关病症的方法和组合物

Country Status (10)

Country Link
US (2) US20130143968A1 (cg-RX-API-DMAC7.html)
EP (2) EP2782588B1 (cg-RX-API-DMAC7.html)
JP (4) JP6089042B2 (cg-RX-API-DMAC7.html)
CN (3) CN103945858A (cg-RX-API-DMAC7.html)
BR (1) BR112014011898A2 (cg-RX-API-DMAC7.html)
ES (1) ES2785094T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257401A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014KN01037A (cg-RX-API-DMAC7.html)
PH (2) PH12020550726B1 (cg-RX-API-DMAC7.html)
WO (1) WO2013077893A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649617A (zh) * 2002-03-01 2005-08-03 日清药业股份有限公司 肝病、高血脂症和糖尿病治疗剂
WO2010107307A1 (en) * 2009-03-20 2010-09-23 Glnp (Generic Life Quality Enhancing Niche Products) Holding B.V. Kit of parts comprising l-glutamine and egcg

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2003072556A1 (en) * 2001-06-27 2003-09-04 Prosidion Ltd. Glutaminyl based dpiv inhibitors
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
WO2008038771A1 (en) * 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Glutamine-containing composition for increasing blood flow
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
HUE034551T2 (en) * 2009-01-12 2018-02-28 Biokier Inc Composition and method for treatment of diabetes
MX2012003459A (es) * 2009-09-23 2012-05-22 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649617A (zh) * 2002-03-01 2005-08-03 日清药业股份有限公司 肝病、高血脂症和糖尿病治疗剂
WO2010107307A1 (en) * 2009-03-20 2010-09-23 Glnp (Generic Life Quality Enhancing Niche Products) Holding B.V. Kit of parts comprising l-glutamine and egcg

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DORIT SAMOCHA-BONET等: "Glutamine Reduces Postprandial Glycemia and Augments the Glucagon-Like Peptide-1 Response in Type 2 Diabetes Patients", 《THE JOURNAL OF NUTRITION》, 18 May 2011 (2011-05-18) *
EMMANUEL C. OPARA等: "L-Glutamine Supplementation of a High Fat Diet Reduces Body Weight and Attenuates Hyperglycemia and Hyperinsulinemia in C57BL/6J Mice", 《NUTRIENT METABOLISM》, 31 December 1996 (1996-12-31) *
JERRY R GREENFIELD等: "Oral glutamine increases circulating glucagon-like peptide 1,glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects", 《AM J CLIN NUTR》, vol. 89, 3 December 2008 (2008-12-03), pages 106 - 113, XP002679635, DOI: 10.3945/ajcn.2008.26362 *
吴亚谋等: "谷氨酰胺对2型糖尿病大鼠血糖和胰岛素抵抗的影响", 《国际麻醉学与复苏杂志》, vol. 32, no. 5, 31 October 2011 (2011-10-31) *

Also Published As

Publication number Publication date
HK1257401A1 (zh) 2019-10-18
EP2782588A1 (en) 2014-10-01
JP6389495B2 (ja) 2018-09-12
BR112014011898A2 (pt) 2017-05-16
JP2014533689A (ja) 2014-12-15
JP6089042B2 (ja) 2017-03-01
PH12020550726A1 (en) 2021-06-14
US20190192463A1 (en) 2019-06-27
EP3437649A1 (en) 2019-02-06
PH12014501052B1 (en) 2020-10-09
PH12014501052A1 (en) 2014-06-30
JP2018199692A (ja) 2018-12-20
JP6550160B2 (ja) 2019-07-24
CN108354916A (zh) 2018-08-03
EP2782588A4 (en) 2015-05-20
PH12020550726B1 (en) 2022-11-09
ES2785094T3 (es) 2020-10-05
US20130143968A1 (en) 2013-06-06
IN2014KN01037A (cg-RX-API-DMAC7.html) 2015-10-09
CN108478551A (zh) 2018-09-04
JP2018115175A (ja) 2018-07-26
JP2017052766A (ja) 2017-03-16
EP2782588B1 (en) 2020-04-15
WO2013077893A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
JP5000493B2 (ja) インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット
CN103285394B (zh) 使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
JP2009532372A (ja) 代謝障害の併用治療
JP2007528886A (ja) 肥満の治療又は予防用のメトホルミン及びオルリスタットの使用
US20190192463A1 (en) Methods and compositions for the treatment of diabetes and related systems
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
JP5063369B2 (ja) メグリチニド類を含有する肝臓線維化予防用医薬組成物
JP6412241B2 (ja) 肝機能改善法
JP2024177198A (ja) グルコース代謝障害の長時間作用型の予防または治療に使用するためのβ－ラクタム化合物またはその塩
EP3582767B1 (fr) Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal
CA2615118A1 (en) Pharmaceutical composition containing ppar.gamma. agonist
CN116911513A (zh) 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
JP2006519881A5 (cg-RX-API-DMAC7.html)
ES2379165T3 (es) Uso de un agonista de PPAR-alfa para tratar la ganancia de peso asociada con un tratamiento con un agonista de PPAR-Gamma
JP6047004B2 (ja) 安全な医薬組成物
BR122024026316A2 (pt) Usos de um composto para prevenção ou tratamento de ação prolongada de um transtorno de metabolismo de glicose
HK1111620A (en) Pharmaceutical composition containing ppar gamma agonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140723

RJ01 Rejection of invention patent application after publication